Main Menu

Urovant Sciences Ltd.

(NASDAQ GS: UROV)

Rigrodsky & Long is investigating Urovant Sciences Ltd. (“Urovant”) regarding possible breaches of fiduciary duties and other violations of law related to Urovant's agreement to be acquired by Sumitovant Biopharma Ltd.  Under the terms of the agreement, Urovant's shareholders will receive $16.25 in cash per share.

Join This Action

Alternatively, you may upload your transactions using the upload button below or email them to info@rl-legal.com.

Draw your signature below using your mouse* [Clear]

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: 11/26/2020


* Indicates a required field.

Back to Page